BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, Fridman WH, Tartour E. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010;32:946-58. [PMID: 20191626 DOI: 10.1002/hed.21346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 29] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Outh-gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C. Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures. Annales de Pathologie 2017;37:79-89. [DOI: 10.1016/j.annpat.2016.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Nizard M, Diniz MO, Roussel H, Tran T, Ferreira LC, Badoual C, Tartour E. Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother 2014;10:2175-87. [PMID: 25424921 DOI: 10.4161/hv.29269] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
3 Kang TH, Park JH, Yang A, Park HJ, Lee SE, Kim YS, Jang GY, Farmer E, Lam B, Park YM, Hung CF. Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nat Commun 2020;11:1137. [PMID: 32111835 DOI: 10.1038/s41467-020-14821-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Queiroz CJ, Nakata CM, Solito E, Damazo AS. Relationship between HPV and the biomarkers annexin A1 and p53 in oropharyngeal cancer. Infect Agent Cancer 2014;9:13. [PMID: 24782913 DOI: 10.1186/1750-9378-9-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Liu H, Zou M, Li P, Wang H, Lin X, Ye J. Oxymatrine‑mediated maturation of dendritic cells leads to activation of FOXP3+/CD4+ Treg cells and reversal of cisplatin‑resistance in lung cancer cells. Mol Med Rep 2019;19:4081-90. [PMID: 30896871 DOI: 10.3892/mmr.2019.10064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Hasmim M, Badoual C, Vielh P, Drusch F, Marty V, Laplanche A, de Oliveira Diniz M, Roussel H, De Guillebon E, Oudard S, Hans S, Tartour E, Chouaib S. Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells. BMC Cancer 2013;13:592. [PMID: 24330498 DOI: 10.1186/1471-2407-13-592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grimm M, Feyen O, Hofmann H, Teriete P, Biegner T, Munz A, Reinert S. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol 2016;37:3807-16. [PMID: 26474587 DOI: 10.1007/s13277-015-4224-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
8 Niebler M, Qian X, Höfler D, Kogosov V, Kaewprag J, Kaufmann AM, Ly R, Böhmer G, Zawatzky R, Rösl F, Rincon-Orozco B. Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog 2013;9:e1003536. [PMID: 23935506 DOI: 10.1371/journal.ppat.1003536] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 8.8] [Reference Citation Analysis]
9 Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology. 2012;1:326-333. [PMID: 22737608 DOI: 10.4161/onci.18852] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 77.0] [Reference Citation Analysis]
10 Upreti D, Pathak A, Kung SK. Lentiviral vector-based therapy in head and neck cancer (Review). Oncol Lett 2014;7:3-9. [PMID: 24348811 DOI: 10.3892/ol.2013.1652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D, McHugh J; University of Michigan Head and Neck SPORE Program. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015;51:90-95. [PMID: 25283344 DOI: 10.1016/j.oraloncology.2014.09.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
12 Wansom D, Light E, Thomas D, Worden F, Prince M, Urba S, Chepeha D, Kumar B, Cordell K, Eisbruch A, Taylor J, Moyer J, Bradford C, D'Silva N, Carey T, McHugh J, Wolf G; UM Head Neck SPORE Program. Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. Laryngoscope 2012;122:121-7. [PMID: 22183632 DOI: 10.1002/lary.22133] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 9.5] [Reference Citation Analysis]
13 Qiu J, Peng S, Yang A, Ma Y, Han L, Cheng MA, Farmer E, Hung CF, Wu TC. Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth. Oncoimmunology 2018;7:e1463946. [PMID: 30221059 DOI: 10.1080/2162402X.2018.1463946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 2013;6:147-157. [PMID: 23104434 DOI: 10.1007/s12307-012-0122-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
15 Johnson SD, De Costa AM, Young MR. Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. Cancers (Basel) 2014;6:756-70. [PMID: 24698959 DOI: 10.3390/cancers6020756] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
16 Schuler PJ, Hoffmann TK, Gauler TC, Bergmann C, Brandau S, Lang S. [Immunotherapy of head and neck cancer. Current developments]. HNO 2013;61:559-72. [PMID: 23247754 DOI: 10.1007/s00106-012-2635-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Faghih Z, Abtahi S, Khademi B, Nikfarjam F, Erfani N. Association of OX40 gene polymorphisms (rs17568G/A and rs229811A/C) with head and neck squamous cell carcinoma. Mol Biol Rep 2019;46:2609-16. [PMID: 30923998 DOI: 10.1007/s11033-019-04602-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Dovšak T, Ihan A, Didanovič V, Kansky A, Verdenik M, Hren NI. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer 2018;18:235. [PMID: 29490633 DOI: 10.1186/s12885-018-4136-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol 2017;71:169-76. [PMID: 27751760 DOI: 10.1016/j.oraloncology.2016.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
20 Moskovitz JM, Moy J, Seiwert TY, Ferris RL. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. Oncologist 2017;22:680-93. [PMID: 28507203 DOI: 10.1634/theoncologist.2016-0318] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
21 Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020;9:E675. [PMID: 32138216 DOI: 10.3390/jcm9030675] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
22 de Medeiros MC, Banerjee R, Liu M, Anovazzi G, D'Silva NJ, Junior CR. HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation. Oncotarget 2017;8:60860-74. [PMID: 28977830 DOI: 10.18632/oncotarget.18486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 2017;76:152-66. [PMID: 28324750 DOI: 10.1016/j.ejca.2016.12.035] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
24 Lin SF, Jiang PL, Tsai JS, Huang YY, Lin SY, Lin JH, Liu DZ. Surface assembly of poly(I:C) on polyethyleneimine-modified gelatin nanoparticles as immunostimulatory carriers for mucosal antigen delivery. J Biomed Mater Res B Appl Biomater 2019;107:1228-37. [PMID: 30339742 DOI: 10.1002/jbm.b.34215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
25 Nizard M, Sandoval F, Badoual C, Pere H, Terme M, Hans S, Benhamouda N, Granier C, Brasnu D, Tartour E. Immunotherapy of HPV-associated head and neck cancer: Critical parameters. Oncoimmunology 2013;2:e24534. [PMID: 23894716 DOI: 10.4161/onci.24534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
26 Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010;2010:701657. [PMID: 21437225 DOI: 10.1155/2010/701657] [Cited by in Crossref: 101] [Cited by in F6Publishing: 103] [Article Influence: 9.2] [Reference Citation Analysis]
27 Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Bajoriunas V, Lavinskiene S, Sakalauskas R. The prognostic influence of tumor infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell lung cancer. J Inflamm (Lond) 2015;12:63. [PMID: 26604855 DOI: 10.1186/s12950-015-0108-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
28 Huang HS, Su HY, Li PH, Chiang PH, Huang CH, Chen CH, Hsieh MC. Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Sci Rep 2018;8:7485. [PMID: 29748589 DOI: 10.1038/s41598-018-25944-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
29 Freiser ME, Serafini P, Weed DT. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities. Immunol Res 2013;57:52-69. [PMID: 24218361 DOI: 10.1007/s12026-013-8462-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
30 Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, Bouguin C, Merillon N, Dransart E, Tran T, Quintin-Colonna F, Autret G, Thiebaud M, Suleman M, Riffault S, Wu TC, Launay O, Danel C, Taieb J, Richardson J, Zitvogel L, Fridman WH, Johannes L, Tartour E. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013;5:172ra20. [PMID: 23408053 DOI: 10.1126/scitranslmed.3004888] [Cited by in Crossref: 148] [Cited by in F6Publishing: 142] [Article Influence: 16.4] [Reference Citation Analysis]